Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report)’s stock price traded up 3.5% on Tuesday . The company traded as high as $3.40 and last traded at $3.25. 66,286 shares traded hands during mid-day trading, a decline of 8% from the average session volume of 71,822 shares. The stock had previously closed at $3.14.
Cyclerion Therapeutics Stock Up 3.5 %
The stock’s 50 day moving average is $2.88 and its two-hundred day moving average is $2.86.
Cyclerion Therapeutics Company Profile
Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.
Further Reading
- Five stocks we like better than Cyclerion Therapeutics
- How to Start Investing in Real Estate
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- Investing In Preferred Stock vs. Common Stock
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- What Are Some of the Best Large-Cap Stocks to Buy?
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
